- Afibrinogenemia congenital
- Congenital afibrinogenemia
- The liquid portion of the blood (plasma)
- Fibrinogen (RaiSTAP)
- A blood product containing concentrated fibrinogen (cryoprecipitate) through a vein (transfusion)
Prophylactic therapy should also be considered for patients with recurrent bleeding episodes, CNS hemorrhage, or during pregnancy for women with recurrent miscarriage.
Individuals with afibrinogenemia should consider the following as part of their management plan:
- Consultation with a hematologist/hemostasis specialist, particularly for patients who require fibrinogen replacement therapy.
- Genetic counseling and family studies, especially for individuals with extensive family history or those considering pregnancy.
- Follow-up by a comprehensive bleeding disorder care team experienced in diagnosing and managing inherited bleeding disorders.
- Vaccination with the hepatitis B vaccine because transfusion increases the risk of hepatitis.
- Chen YB, Zieve D. Congenital afibrinogenemia. MedlinePlus. January 27, 2015; http://www.nlm.nih.gov/medlineplus/ency/article/001313.htm.
- Acharya SS. Inherited Abnormalities of Fibrinogen. Medscape Reference. November 18, 2014; http://emedicine.medscape.com/article/960677-overview.
- ClinicalTrials.gov lists trials that are studying or have studied Afibrinogenemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.